PFE vs SBUX: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Starbucks Corporation · Consumer Cyclical
$96.67
+12.3% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
SBUX has more upside to fair value
(+12.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
SBUX |
| Current Price |
$27.64 |
$96.67 |
| Fair Value Estimate |
$30.94 |
$108.52 |
| Upside to Fair Value |
+12.0%
|
+12.3%
|
| Market Cap |
$157.5B |
$110.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
22.0x
|
| Price / Sales |
2.5x
|
2.9x
|
| Price / FCF |
14.3x
|
30.4x
|
| Revenue Growth YoY |
+2.6%
|
-1.4%
|
| Gross Margin |
71.3%
|
31.7%
|
| Operating Margin |
25.1%
|
9.4%
|
| Return on Equity |
4.9%
|
-24.3%
|
| Dividend Yield |
6.22% |
2.57% |
| FCF Yield |
6.97%
|
3.29%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Starbucks is the world's largest specialty coffee retailer, operating company-owned and licensed coffeehouses across North America, International, and Channel Development segments, with a brand that has historically supported premium pricing and global scale. The business quality is currently strained: revenue declined 1.4% year over year in the most recent quarter, TTM operating margin is 9.4%, …
Accumulation Zones
| Metric |
PFE |
SBUX |
| Zone Low |
$23.21 |
$81.39 |
| Zone High |
$26.30 |
$92.24 |
| In Buy Zone? |
No
|
No
|